To our knowledge, our work is the first trial to analyse the effect of the SGLT2 inhibitor empagliflozin on tissue sodium content, assessed non-invasively by 23Na-MRI, in euvolemic patients with CHF under stable conditions. This evidence concerns the gene SLC5A2 and congestive heart failure.